OnKure Therapeutics, Inc. (OKUR)
2.37
-0.16
(-6.14%)
USD |
NASDAQ |
Nov 06, 10:20
OnKure Therapeutics Enterprise Value : -60.24M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -60.24M |
| November 04, 2026 | -57.61M |
| November 03, 2026 | -61.26M |
| November 02, 2026 | -57.61M |
| October 30, 2026 | -56.40M |
| October 29, 2026 | -56.40M |
| October 28, 2026 | -55.99M |
| October 27, 2026 | -57.41M |
| October 26, 2026 | -62.27M |
| October 23, 2026 | -60.45M |
| October 22, 2026 | -58.02M |
| October 21, 2026 | -69.36M |
| October 20, 2026 | -66.93M |
| October 19, 2026 | -71.38M |
| October 16, 2026 | -77.46M |
| October 15, 2026 | -76.24M |
| October 14, 2026 | -71.38M |
| October 13, 2026 | -67.54M |
| October 12, 2026 | -64.50M |
| October 09, 2026 | -64.90M |
| October 08, 2026 | -69.36M |
| October 07, 2026 | -67.33M |
| October 06, 2026 | -62.88M |
| October 05, 2026 | -55.99M |
| October 02, 2026 | -58.83M |
| Date | Value |
|---|---|
| October 01, 2026 | -59.64M |
| September 30, 2026 | -52.14M |
| September 29, 2026 | -70.17M |
| September 28, 2026 | -63.69M |
| September 25, 2026 | -58.02M |
| September 24, 2026 | -56.81M |
| September 23, 2026 | -56.40M |
| September 22, 2026 | -49.92M |
| September 21, 2026 | -51.54M |
| September 18, 2026 | -56.00M |
| September 17, 2026 | -55.59M |
| September 16, 2026 | -58.83M |
| September 15, 2026 | -56.81M |
| September 14, 2026 | -53.97M |
| September 11, 2026 | -49.92M |
| September 10, 2026 | -43.04M |
| September 09, 2026 | -38.58M |
| September 08, 2026 | -37.77M |
| September 04, 2026 | -30.48M |
| September 03, 2026 | -31.29M |
| September 02, 2026 | -32.10M |
| September 01, 2026 | -31.29M |
| August 31, 2026 | -28.46M |
| August 28, 2026 | -21.98M |
| August 27, 2026 | -20.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Heron Therapeutics, Inc. | 159.79M |
| Tonix Pharmaceuticals Holding Corp. | -97.72M |
| Karyopharm Therapeutics, Inc. | 192.45M |
| Minerva Neurosciences, Inc. | 105.00M |
| Corbus Pharmaceuticals Holdings, Inc. | -60.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.85M |
| Total Expenses (Quarterly) | 17.85M |
| EPS Diluted (Quarterly) | -0.3574 |
| Earnings Yield | -116.7% |
| Normalized Earnings Yield | -116.73 |